The US Food and Drug Administration (FDA) on Friday said that it would delay an appointment scheduled for next week, where a panel of experts will decide whether to approve the Pfizer-BioNTech Covid vaccination for infants.
The meeting was supposed to have analyzed what dose should be permitted for children ranging from 6 months to 4 years old although clinical trials are still being conducted to determine whether three shots are required.
In fact, interim results found that a small dose of 3 micrograms in this age group to ward off adverse effects did not trigger an immune response similar to those of older age groups receiving an increased dose.
It is important to note that even after 2 years since this pandemic gripped the world, there is not much advancement by any major countries in terms of announcing vaccines for kids. Despite many pharma companies working actively in development of an effective vaccine, there is no official launch yet.
Bob is a Digital Entrepreneur and keen follower of the Crypto and Blockchain world. He enjoys exploring the latest technology and news related to Fintech world. He is a go-to person with a positive attitude towards life.